# A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)

Source: https://onco.cc/trials/nct07234162/  
OnCo record `nct07234162` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Golidocitinib run by Dizal Pharmaceuticals, now recruiting.

## Summary

A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19) is a phase 3 interventional study registered as NCT07234162 by Dizal Pharmaceuticals, with 218 participants planned, started 2024-05-13. Conditions listed: Peripheral T-cell Lymphoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07234162
- Phase: 3
- Setting: A Phase 3, Open-Label, Randomized, Multinational Study to Investigate the Anti-tumor Efficacy of Golidocitinib Versus Investigator's Choice in Adult Patients With Relapsed/Refractory Peripheral T-cell Lymphoma
- Sponsor: Dizal Pharmaceuticals
- Enrolled: 218

## Sources

- ClinicalTrials.gov NCT07234162: https://clinicaltrials.gov/study/NCT07234162

## Connected records

- drugs: [Golidocitinib](https://onco.cc/drugs/golidocitinib/)
- companies: [Dizal Pharmaceutical](https://onco.cc/companies/dizal/)

---
JSON: https://onco.cc/api/v1/entities/nct07234162.json